Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
16hon MSN
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.
Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results